Short answer
biote Corp. (BTMD) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $48M (down 6.7% year over year) with net income of $8M.
Q3 2025 key financials · XBRL
- Revenue
- $48M
- −6.7% YoY · −1.9% QoQ
- Net income
- $8M
- +4.4% YoY · +157.1% QoQ
- Operating margin
- 17.2%
- EPS (diluted)
- $0.22
- −4.3% YoY · +144.4% QoQ
Source: XBRL data from the biote Corp. (BTMD) Q3 2025 10-Q on SEC EDGAR. USD.
biote Corp. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin figures reported for the quarter or YoY comparisons
- $3.5 million settlement payment to Right Value on Feb 28, 2025; $1.5 million accrued liability remains as of Sep 30, 2025
- Management highlights ongoing unresolved material weakness in internal controls over financial reporting, remediation efforts continuing with no assurance of timely resolution
- Multiple ongoing litigations including Right Value settlement and Donovitz share repurchase agreement for $18.5 million scheduled Jan 2026, impacting future cash outflows; outlook cautions on legal uncertainties
Risk Factors
- New risk: Share repurchase program authorized up to $20.0M, with $11.0M remaining as of Sept 30, 2025, introducing potential stock price volatility
- Material update: Rising tariffs on estradiol from China and trocars from Pakistan increasing raw material costs and supply chain risks
- Regulatory risk: Complex tariff rules may expose company to civil/criminal trade compliance actions in U.S. and foreign jurisdictions
- Market risk: Geopolitical tensions and trade disputes causing inflationary pressures, FX volatility, and reduced customer demand
- Financial risk: Share repurchases totaling 1.01M shares for $3.4M in Q3 2025, affecting cash liquidity and capital allocation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other biote Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.